Cellcom Israel Stock Forecast, Price & News

Cellcom Israel's stock was trading at $2.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CEL shares have increased by 56.2% and is now trading at $3.78.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellcom Israel in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cellcom Israel.

Cellcom Israel is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020.
View our earnings forecast for Cellcom Israel.

Cellcom Israel Ltd. (NYSE:CEL) announced its quarterly earnings data on Thursday, May, 21st. The technology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.09. The technology company earned $250 million during the quarter. Cellcom Israel had a negative net margin of 4.05% and a negative return on equity of 8.08%.
View Cellcom Israel's earnings history.

Cellcom Israel saw a decline in short interest in August. As of August 14th, there was short interest totaling 56,400 shares, a decline of 14.4% from the July 30th total of 65,900 shares. Based on an average trading volume of 16,700 shares, the short-interest ratio is presently 3.4 days. Currently, 0.1% of the shares of the company are sold short.
View Cellcom Israel's Short Interest.

Some companies that are related to Cellcom Israel include HUTCHISON TELEC/ADR (HTHKY), Partner Communications (PTNR), Spok (SPOK), Pharol SGPS (PTGCY), Iridium World Communications (IRIDQ), m-Wise (MWIS) and ZIM (ZIMCF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellcom Israel investors own include Pfizer (PFE), Verizon Communications (VZ), Bank of America (BAC), Citigroup (C), General Electric (GE), Gilead Sciences (GILD), General Motors (GM), Intel (INTC), Teva Pharmaceutical Industries (TEVA) and Wells Fargo & Company (WFC).

Cellcom Israel trades on the New York Stock Exchange (NYSE) under the ticker symbol "CEL."

Cellcom Israel's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Meitav Dash Investments Ltd. (0.24%), Swiss National Bank (0.12%), Goldman Sachs Group Inc. (0.02%), Harel Insurance Investments & Financial Services Ltd. (0.02%), Jane Street Group LLC (0.01%) and State of Wisconsin Investment Board (0.01%).
View institutional ownership trends for Cellcom Israel.

CEL stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Jane Street Group LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Cellcom Israel.

CEL stock was purchased by a variety of institutional investors in the last quarter, including Swiss National Bank, Meitav Dash Investments Ltd., and State of Wisconsin Investment Board.
View insider buying and selling activity for Cellcom Israel.

Shares of CEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CEL stock can currently be purchased for approximately $3.78.

Cellcom Israel has a market capitalization of $563.85 million and generates $1.07 billion in revenue each year. Cellcom Israel employs 3,265 workers across the globe.

The official website for Cellcom Israel is www.cellcom.co.il.

Cellcom Israel's mailing address is 10 HAGAVISH STREET, NETANYA L3, 4250708. The technology company can be reached via phone at 972-52-998-9595 or via email at [email protected]